FDA verdict for Cubist antibiotic tedizolid expected in June; priority granted
This article was originally published in Scrip
Shares of Cubist Pharmaceuticals nudged up 1.6%, or $1.09, in morning trading on 30 December on the news the FDA granted a priority review of the firm's new drug application (NDA) for its experimental antibiotic tedizolid phosphate (TR-701).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.